Neumora Therapeutics Inc
Company Profile
Business description
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.
Contact
490 Arsenal Way
Suite 200
WatertownMA02472
USAT: +1 857 760-0900
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
103
Stocks News & Analysis
stocks
Insignia Financial: Revised deal still attractive
stocks
Going into earnings, is Alphabet stock a buy, a sell, or fairly valued?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,001.40 | 59.90 | 0.67% |
| CAC 40 | 7,850.43 | 106.02 | 1.37% |
| DAX 40 | 24,240.82 | 198.92 | 0.83% |
| Dow JONES (US) | 45,010.60 | 508.16 | 1.14% |
| FTSE 100 | 9,061.49 | 37.68 | 0.42% |
| HKSE | 25,538.07 | 408.04 | 1.62% |
| NASDAQ | 21,020.02 | 127.33 | 0.61% |
| Nikkei 225 | 41,171.32 | 1,396.40 | 3.51% |
| NZX 50 Index | 12,794.06 | 39.68 | -0.31% |
| S&P 500 | 6,359.05 | 49.43 | 0.78% |
| S&P/ASX 200 | 8,737.20 | 60.00 | 0.69% |
| SSE Composite Index | 3,582.30 | 0.44 | 0.01% |